- IP hearings this week
- IP trials
- IP Judicial review hearings
- IP appeals at the Federal Court of Appeal
(As published on the Federal Court and Federal Court of Appeal websites on Nov 28, 2022 at 00:00:00)
This week in IP
| Date | File No. | Type | Name | Location | Length |
| Nov 28, 2022 | A-78-22 | APP | Agc V. Catalyst Pharmaceuticals Inc. Et Al (unknown) | Toronto | 1 d |
| Nov 28, 2022 | T-841-21 | CMC | Rovi Guides, Inc. V. Videotron Ltd. (Patent) | Toronto | 30 m |
| Nov 29, 2022 | T-1517-21 | M | Hudson's Bay Company Ulc V. Zellers Inc. Et Al. (Trade Mark) | Toronto | 10 m |
| Nov 29, 2022 | T-2276-22 | CMC | Boehringer Ingelheim (canada) Ltd Et Al. V. Jamp Pharma Corporation (Patent - Empagliflozin*) | Toronto | 30 m |
| Nov 29, 2022 | T-2318-22 | CMC | Boehringer Ingelheim (canada) Ltd. Et Al. V. Jamp Pharma Corporation (Patent - Empagliflozin*) | Toronto | 30 m |
| Nov 29, 2022 | T-2307-22 | CMC | Astrazeneca Canada Inc. Et Al V. Pharmascience Inc. (Patent - Dapagliflozin*) | Toronto | 30 m |
| Nov 29, 2022 | T-1838-22 | CMC | Amgen Canada Inc. Et Al. V. Sandoz Canada Inc. (Patent - Carfilzomib*) | Toronto | 30 m |
| Nov 29, 2022 | T-1750-22 | CMC | Actelion Pharmaceuticals Ltd Et Al. V. Sandoz Canada Inc. (Patent - Selexipag*) | Toronto | 30 m |
| Nov 30, 2022 | T-1257-22 | CMC | Bell Media Ind Et Al. V. Marshall Macciacchera Et Al (Copyright) | Ottawa | 1 h |
| Nov 30, 2022 | T-1645-16 | M | Arkipelago Architecture Inc. V. Enghouse Systems Limited Et Al (Copyright) | Toronto | 2 h |
| Nov 30, 2022 | T-717-20 | CMC | Gold Line Telemanagement Inc. Et Al. V. Ereele Gmbh (Trade Mark) | Montréal | 1 h |
| Nov 30, 2022 | T-451-20 | CMC | Kobold Corporation Et Al. V. Ncs Multistage Inc. (Patent) | Toronto | 30 m |
| Dec 1, 2022 | T-1059-22 | CMC | Seylynn (north Shore) Development Limited Partnership V. Denna Homes Group (Trade Mark) | Vancouver | 30 m |
| Dec 1, 2022 | T-1493-22 | CMC | Abo Taheri V. Denna Homes Group (unknown) | Vancouver | 30 m |
| Dec 1, 2022 | T-165-21 | MSJ | 7294140 Canada Inc. Dba Zoomtoner V. Connexlogix Inc. Et Al. (Trade Mark) | Montréal | 1.3 d |
| Dec 1, 2022 | T-1213-21 | M | Lundbeck Canada Inc. Et Al. V. Apotex Inc. Et Al. (Patent - Vortioxetine*) | Toronto | 1.5 h |
| Dec 1, 2022 | T-668-21 | M | Lundbeck Canada Inc. Et Al. V. Apotex Inc. Et Al. (Patent - Vortioxetine*) | Toronto | 1.5 h |
| Dec 1, 2022 | T-919-21 | CMC | Maoz Betser-zilevitch V. Canadian Natural Resources Ltd. (Patent) | Ottawa | 1 h |
| Dec 1, 2022 | T-1269-22 | M | Ark Innovation Technology Inc. V. 2xm Creations Inc. Et Al. (Copyright) | Vancouver | 2 h |
Return to top.
Scheduled IP Trials
| Date | File No. | Name | Location | Length |
| Nov 14, 2022 | T-557-21 | Abbvie Corporation, Et Al V. Jamp Pharma Corporation (Patent - Adalimumab*) | Toronto | 20 d |
| Nov 14, 2022 | T-559-21 | Abbvie Corporation, Et Al V. Jamp Pharma Corporation (Patent - Adalimumab*) | Toronto | 20 d |
| Nov 14, 2022 | T-560-21 | Abbvie Corporation, Et Al V. Jamp Pharma Corporation (Patent - Adalimumab*) | Toronto | 20 d |
| Nov 14, 2022 | T-561-21 | Abbvie Corporation, Et Al V. Jamp Pharma Corporation (Patent - Adalimumab*) | Toronto | 20 d |
| Nov 14, 2022 | T-572-21 | Jamp Pharma Corporation V. Abbvie Corporation Et Al. (Patent - Adalimumab*) | Toronto | 20 d |
| Nov 14, 2022 | T-573-21 | Jamp Pharma Corporation V. Abbvie Corporation Et Al. (Patent - Adalimumab*) | Toronto | 20 d |
| Nov 14, 2022 | T-577-21 | Jamp Pharma Corporation V. Abbvie Corporation Et Al. (Patent - Adalimumab*) | Toronto | 20 d |
| Nov 14, 2022 | T-581-21 | Jamp Pharma Corporation V. Abbvie Corporation Et Al. (Patent - Adalimumab*) | Toronto | 20 d |
| Dec 5, 2022 | T-1213-21 | Lundbeck Canada Inc. Et Al. V. Apotex Inc. Et Al. (Patent - Vortioxetine*) | Toronto | 10 d |
| Dec 5, 2022 | T-668-21 | Lundbeck Canada Inc. Et Al. V. Apotex Inc. Et Al. (Patent - Vortioxetine*) | Toronto | 10 d |
| Dec 13, 2022 | T-581-21 | Jamp Pharma Corporation V. Abbvie Corporation Et Al. (Patent - Adalimumab*) | Toronto | 2 d |
| Dec 13, 2022 | T-557-21 | Abbvie Corporation, Et Al V. Jamp Pharma Corporation (Patent - Adalimumab*) | Toronto | 2 d |
| Dec 13, 2022 | T-559-21 | Abbvie Corporation, Et Al V. Jamp Pharma Corporation (Patent - Adalimumab*) | Toronto | 2 d |
| Dec 13, 2022 | T-560-21 | Abbvie Corporation, Et Al V. Jamp Pharma Corporation (Patent - Adalimumab*) | Toronto | 2 d |
| Dec 13, 2022 | T-561-21 | Abbvie Corporation, Et Al V. Jamp Pharma Corporation (Patent - Adalimumab*) | Toronto | 2 d |
| Dec 13, 2022 | T-572-21 | Jamp Pharma Corporation V. Abbvie Corporation Et Al. (Patent - Adalimumab*) | Toronto | 2 d |
| Dec 13, 2022 | T-573-21 | Jamp Pharma Corporation V. Abbvie Corporation Et Al. (Patent - Adalimumab*) | Toronto | 2 d |
| Dec 13, 2022 | T-577-21 | Jamp Pharma Corporation V. Abbvie Corporation Et Al. (Patent - Adalimumab*) | Toronto | 2 d |
| Jan 9, 2023 | T-1007-20 | Medexus Pharmaceuticals Inc. Et Al. V. Accord Healthcare Inc. Et Al (Patent) | Toronto | 14 d |
| Feb 13, 2023 | T-512-20 | 2660722 Ontario Inc. Et Al. V. Vanpak Limited Et Al. (unknown) | Ottawa | 10 d |
| Feb 20, 2023 | T-343-20 | The Noco Company, Inc. V. Canadian Tire Corporation, Limited (Patent) | Toronto | 7 d |
| Feb 20, 2023 | T-374-21 | Vidã?otron Ltã?e Et Al C. Technologies Konek Inc. Et Al (Copyright) | Montréal | 8 d |
| Feb 27, 2023 | T-788-21 | Boehringer Ingelheim (canada) Ltd. Et Al V. Jamp Pharma Corporation (Patent - Linagliptin*) | Toronto | 4 d |
| Mar 3, 2023 | T-343-20 | The Noco Company, Inc. V. Canadian Tire Corporation, Limited (Patent) | Toronto | 1 d |
| Mar 6, 2023 | T-788-21 | Boehringer Ingelheim (canada) Ltd. Et Al V. Jamp Pharma Corporation (Patent - Linagliptin*) | Toronto | 4 d |
| Mar 13, 2023 | T-788-21 | Boehringer Ingelheim (canada) Ltd. Et Al V. Jamp Pharma Corporation (Patent - Linagliptin*) | Toronto | 4 d |
| Mar 20, 2023 | T-703-20 | Kaira District Coop Milk Producers Union Ltd Et Al V Amul Canada Ltd Et Al (Trade Mark) | Toronto | 5 d |
| Mar 23, 2023 | T-788-21 | Boehringer Ingelheim (canada) Ltd. Et Al V. Jamp Pharma Corporation (Patent - Linagliptin*) | Toronto | 2 d |
| Apr 11, 2023 | T-711-20 | Bell Canada V. Skychoice Communications Inc. (Trade Mark) | Toronto | 8 d |
| Apr 17, 2023 | T-609-20 | Wanakome Inc. V. Eric Martin Et Al. (Trade Mark) | Montréal | 10 d |
| Apr 17, 2023 | T-127-19 | Fromfroid S.a. C. 1048547 Ontario Inc. Et Al. (Patent) | Montréal | 5 d |
| May 8, 2023 | T-1924-17 | Bell Canada Et Al V. Watchnsavenow Inc. Et Al (Copyright) | Toronto | 10 d |
| Jun 5, 2023 | T-1168-21 | Dr. Reddy's Laboratories Ltd. Et Al V. Janssen Inc, Et Al (PMNOC - Section 8 - Abiraterone*) | Toronto | 10 d |
| Jun 5, 2023 | T-1966-21 | Bausch Health Ireland Ltd Et Al V. Apotex Inc. (Patent - Efinaconazole*) | To be determined (TrialJA) | 8 d |
| Jun 5, 2023 | T-379-21 | Molo Design, Ltd. V. Chanel Canada Ulc Et Al. (Patent) | Montréal | 10 d |
| Jun 19, 2023 | T-1966-21 | Bausch Health Ireland Ltd Et Al V. Apotex Inc. (Patent - Efinaconazole*) | To be determined (TrialJA) | 2 d |
| Jun 19, 2023 | T-607-21 | Apotex Inc. V. Janssen Inc. Et Al. (PMNOC - Section 8 - Abiraterone*) | Toronto | 10 d |
| Jun 26, 2023 | T-17-16 | Ducks Lane Ltd. Et Al V. Outforont Media Llc Et Al (Trade Mark) | Toronto | 5 d |
| Jul 10, 2023 | T-1472-21 | Pharmacyclics Llc Et Al. V. Natco Pharma (canada) Inc. (Patent - Ibrutinib*) | Toronto | 15 d |
| Jul 10, 2023 | T-1475-21 | Pharmacyclics Llc Et Al. V. Natco Pharma (canada) Inc. (Patent - Ibrutinib*) | Toronto | 15 d |
| Sep 11, 2023 | T-1962-21 | Bausch Health Ireland Ltd Et Al V. Apotex Inc. (Patent - Efinaconazole*) | To be determined (TrialJA) | 5 d |
| Sep 11, 2023 | T-1994-21 | Allergan, Inc. Et Al. V. Juno Pharmaceuticals Corp. (Patent - Bimatoprost*) | Toronto | 10 d |
| Sep 21, 2023 | T-1962-21 | Bausch Health Ireland Ltd Et Al V. Apotex Inc. (Patent - Efinaconazole*) | To be determined (TrialJA) | 2 d |
| Sep 25, 2023 | T-1869-21 | Bayer Inc. Et Al. V. Sandoz Canada Inc. (Patent - Riociguat*) | Toronto | 2 d |
| Oct 3, 2023 | T-1869-21 | Bayer Inc. Et Al. V. Sandoz Canada Inc. (Patent - Riociguat*) | Toronto | 4 d |
| Oct 3, 2023 | T-15-22 | Boehringer Ingleheim (canada) Ltd. Et Al. V. Pharmascience Inc. (Patent - Linagliptin*) | Toronto | 16 d |
| Oct 10, 2023 | T-1869-21 | Bayer Inc. Et Al. V. Sandoz Canada Inc. (Patent - Riociguat*) | Toronto | 4 d |
| Oct 16, 2023 | T-151-22 | Takeda Canada V. Apotex, Takeda Pharmaceutical Co & Takeda Pharma Usa (Patent - Dexlansoprazole*) | To be determined (TrialJA) | 10 d |
| Oct 16, 2023 | T-653-21 | Apotex Inc. V. Servier Canada Inc. (Patent - Perindopril*) | Toronto | 10 d |
| Oct 30, 2023 | T-192-22 | Novartis Pharmaceuticals Canada Inc. Et Al. V. Teva Canada Limited (Patent - Sacubitril*) | Ottawa | 10 d |
| Nov 9, 2023 | T-151-22 | Takeda Canada V. Apotex, Takeda Pharmaceutical Co & Takeda Pharma Usa (Patent - Dexlansoprazole*) | To be determined (TrialJA) | 2 d |
| Nov 20, 2023 | T-1386-21 | Jcai Inc. V. Wiseleap Solutions Inc. Et Al (Patent) | To be determined (TrialJA) | 12 d |
| Jan 8, 2024 | T-1004-22 | Gilead Sciences, Inc. Et Al V. Apotex Inc. (Patent - Tenofovir*) | Toronto | 13 d |
| Jan 8, 2024 | T-1006-22 | Gilead Sciences, Inc. Et Al V. Apotex Inc. (Trade Mark - Tenofovir*) | Toronto | 13 d |
| Feb 5, 2024 | T-1004-22 | Gilead Sciences, Inc. Et Al V. Apotex Inc. (Patent - Tenofovir*) | Toronto | 2 d |
| Feb 5, 2024 | T-1006-22 | Gilead Sciences, Inc. Et Al V. Apotex Inc. (Trade Mark - Tenofovir*) | Toronto | 2 d |
| Feb 12, 2024 | T-997-22 | Janssen Pharmaceutica N. V. V. Apotex Inc. (Patent - Rilpivirine*) | Toronto | 7 d |
| Feb 29, 2024 | T-997-22 | Janssen Pharmaceutica N. V. V. Apotex Inc. (Patent - Rilpivirine*) | Toronto | 2 d |
| Mar 4, 2024 | T-1484-22 | Gilead Sciences, Inc. Et Al. V. Jamp Pharma Corporation (Patent - Tenofovir*) | Toronto | 10 d |
| Mar 4, 2024 | T-1607-22 | Gilead Sciences, Inc. Et Al. V. Jamp Pharma Corporaton (Patent - Tenofovir*) | Toronto | 10 d |
| Mar 11, 2024 | T-1187-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 13 d |
| Mar 11, 2024 | T-1188-22 | Boehringer Ingelheim (canada) Ltd. Et Al V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 13 d |
| Mar 11, 2024 | T-1175-22 | Boehringer Ingelheim (canada) Ltd. Et Al V. Apotex Inc. (Patent) | Toronto | 13 d |
| Mar 11, 2024 | T-1176-22 | Boehringer Ingelheim (canada) Ltd. Et Al V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 13 d |
| Mar 11, 2024 | T-1178-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 13 d |
| Mar 11, 2024 | T-1181-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 13 d |
| Mar 18, 2024 | T-1121-22 | Janssen Inc. Et Al V. Apotex Inc. (Patent - Paliperidone*) | Toronto | 5 d |
| Mar 18, 2024 | T-1122-22 | Janssen Inc. Et Al V. Apotex Inc. (Patent - Paliperidone*) | Toronto | 5 d |
| Mar 18, 2024 | T-1248-22 | Janssen Inc. Et Al. V. Apotex Inc. (Patent - Paliperidone*) | Toronto | 5 d |
| Mar 18, 2024 | T-1249-22 | Janssen Inc. Et Al. V. Apotex Inc. (Patent - Paliperidone*) | Toronto | 5 d |
| Mar 25, 2024 | T-1484-22 | Gilead Sciences, Inc. Et Al. V. Jamp Pharma Corporation (Patent - Tenofovir*) | Toronto | 2 d |
| Mar 25, 2024 | T-1607-22 | Gilead Sciences, Inc. Et Al. V. Jamp Pharma Corporaton (Patent - Tenofovir*) | Toronto | 2 d |
| Apr 4, 2024 | T-1187-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 2 d |
| Apr 4, 2024 | T-1188-22 | Boehringer Ingelheim (canada) Ltd. Et Al V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 2 d |
| Apr 4, 2024 | T-1175-22 | Boehringer Ingelheim (canada) Ltd. Et Al V. Apotex Inc. (Patent) | Toronto | 2 d |
| Apr 4, 2024 | T-1176-22 | Boehringer Ingelheim (canada) Ltd. Et Al V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 2 d |
| Apr 4, 2024 | T-1178-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 2 d |
| Apr 4, 2024 | T-1181-22 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Apotex Inc. (Patent - Linagliptin*) | Toronto | 2 d |
| Apr 8, 2024 | T-1555-22 | Gilead Sciences, Inc. Et Al. V. Natco Pharma (canada), Inc. (Patent - Tenofovir*) | Toronto | 9 d |
| Apr 8, 2024 | T-1556-22 | Gilead Sciences, Inc. Et Al. V. Natco Pharma (canada) Inc. (Patent - Tenofovir*) | Toronto | 9 d |
| Apr 29, 2024 | T-1556-22 | Gilead Sciences, Inc. Et Al. V. Natco Pharma (canada) Inc. (Patent - Tenofovir*) | Toronto | 1 d |
| Apr 29, 2024 | T-1555-22 | Gilead Sciences, Inc. Et Al. V. Natco Pharma (canada), Inc. (Patent - Tenofovir*) | Toronto | 1 d |
| Apr 29, 2024 | T-1337-22 | Merck Sharp & Dohme Llc Et Al. V. Pharmascience Inc. (Patent - Sitagliptin*) | Toronto | 3 d |
| May 3, 2024 | T-1337-22 | Merck Sharp & Dohme Llc Et Al. V. Pharmascience Inc. (Patent - Sitagliptin*) | Toronto | 1 d |
| May 6, 2024 | T-1563-22 | Boehringer Ingelheim(canada) Ltd Et Al V. Jamp Pharma Corp. (Patent - Nintedanib*) | Toronto | 10 d |
| May 7, 2024 | T-1750-22 | Actelion Pharmaceuticals Ltd Et Al. V. Sandoz Canada Inc. (Patent - Selexipag*) | Toronto | 9 d |
| May 24, 2024 | T-1750-22 | Actelion Pharmaceuticals Ltd Et Al. V. Sandoz Canada Inc. (Patent - Selexipag*) | Toronto | 1 d |
| May 27, 2024 | T-1482-22 | Bayer Inc. Et Al. V. Bgp Pharma Ulc D.b.a. Viatris Canada Et Al. (Patent - Aflibercept*) | To be determined (TrialJA) | 10 d |
| May 27, 2024 | T-1766-22 | Bayer Inc. Et Al V. Bgp Pharma Ulc D.b.a. Viatris Canada (Patent - Aflibercept*) | To be determined (TrialJA) | 10 d |
| May 27, 2024 | T-1563-22 | Boehringer Ingelheim(canada) Ltd Et Al V. Jamp Pharma Corp. (Patent - Nintedanib*) | Toronto | 2 d |
| May 27, 2024 | T-1838-22 | Amgen Canada Inc. Et Al. V. Sandoz Canada Inc. (Patent - Carfilzomib*) | Toronto | 12 d |
| Jun 14, 2024 | T-1838-22 | Amgen Canada Inc. Et Al. V. Sandoz Canada Inc. (Patent - Carfilzomib*) | Toronto | 6 d |
| Jul 2, 2024 | T-1838-22 | Amgen Canada Inc. Et Al. V. Sandoz Canada Inc. (Patent - Carfilzomib*) | Toronto | 2 d |
| Nov 18, 2024 | T-1462-22 | Merck Sharp And Dohme Llc Et Al V. Pharmascience Inc. Et Al (Patent - Sitagliptin*) | Toronto | 10 d |
| Dec 9, 2024 | T-1462-22 | Merck Sharp And Dohme Llc Et Al V. Pharmascience Inc. Et Al (Patent - Sitagliptin*) | Toronto | 1 d |
Return to top.
Scheduled Judicial Review Hearings
| Date | File No. | Name | Type | Location | Length |
| Dec 14, 2022 | T-1867-21 | Janssen Inc. V. Attorney General Of Canada Et Al. | S. 18.1 Application for Judicial Review | Toronto | 1 d |
| Feb 2, 2023 | T-1172-21 | Standard International Management Llc V. Asia Standard Management Services L | Trade Mark - Appeal of a decision of the Registrar | Toronto | 1 d |
| Feb 2, 2023 | T-424-22 | Empire Comfort Systems, Inc. V. Onward Multi-corp Inc. | Trade Mark - Appeal of a decision of the Registrar | Ottawa | 1 d |
| Feb 2, 2023 | T-423-22 | Empire Comfort Systems, Inc. V. Onward Multi-corp Inc. | Trade Mark - Appeal of a decision of the Registrar | Ottawa | 1 d |
| Apr 17, 2023 | T-1664-22 | Novartis Ag Et Al V. Biogen, Inc. Et Al | Trade Mark Infringement | Toronto | 2 d |
Return to top.
Scheduled IP Appeals
| Date | File No. | Name | Type | Location | Length |
| Nov 28, 2022 | A-78-22 | Agc V. Catalyst Pharmaceuticals Inc. Et Al | Appeal (S.27 - Final) - Statutory Appeal [from T-1047-21 - S. 18.1 Application for Judicial Review] | Toronto | 1 d |
* Medicinal ingredients are based on automated analysis and should not be relied upon.
Return to top.